Old drugs, new hope? ceritinib and docetaxel team up against tough lung cancer
NCT ID NCT03611738
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase study tests whether combining two cancer drugs—ceritinib and docetaxel—can safely help people with advanced non-small cell lung cancer that has not responded to other treatments. About 21 adults with stage IIIB or IV disease will receive the drugs to find the best dose and see if tumors shrink. The goal is to control the cancer, not cure it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ceritinib (Zykadia) and docetaxel (Taxotere)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with advanced non-small cell lung cancer who have few alternatives.
What could go wrong
This is a very early Phase 1 trial with only 21 participants, so it is primarily testing safety and dosing. The combination may not shrink tumors or improve survival, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advent Health Orlando
Orlando, Florida, 32804, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States